StockIQ.techRegeneron Pharmaceuticals Inc. (REGN) Stock Analysis
Free AI-powered analysis and research for Regeneron Pharmaceuticals Inc. stock
Sector: Healthcare
REGN snapshot
Data as of 9 Oct 2026 close. Updated daily.
Regeneron Pharmaceuticals Inc. scores 86/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 65% of its 52-week range, up 32.2% over the past year. Latest reported figures show a profit margin of 27.9%, return on equity of 14.0% and revenue growth of +16.7%.
What is driving the score
- RSI Oversold: +15
- Strong Downtrend: -12
- MACD Bearish: -8
- Strong Revenue Growth (16.7%): +8
- Excellent Profit Margin (27.9%): +10
- Low Debt (0.09 D/E): +8
- Strong Liquidity (3.33 Current Ratio): +8
- Above MA200: +4
- Strong Momentum (+32.2% over 1 year): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full REGN report
Regeneron Pharmaceuticals Inc. (REGN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze REGN Now →📰 Latest Update
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
Tue, September 15, 2026 at 2:14 PM UTC 4 min read
Regeneron Pharmaceuticals (REGN) is facing lawsuits related to misstatements about its Fianlimab-Libtayo trial, which could impact the company's credibility and pipeline prospects. Investors are concerned that these legal challenges may hinder the development of key therapies and affect future revenue streams. The outcome of these lawsuits could significantly influence REGN's stock performance and investor sentiment moving forward.